PIK3CA and breast carcinoma: The other targets are currently being evaluated for treatment of breast cancer patients in clinical trials including: Ras/Raf/MAPK [12], [13], Phosphoinositide-3-kinase (PI3K) [14], Insulin-like Growth Factor 1 Receptor (IGF1R) [15], c-src (CSK) [16], Heat Shock Protein (HSP90) [17], and the epigenetic modulator Histone Deacetylase (HDAC) [18].